SCHEMBL4551968

SCHEMBL4551968

Cc1ccc(S(=O)(=O)N(C)CC(=O)N[C@@H](Cc2ccc(OC(=O)N3CCOCC3)cc2)C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.45
HPGD P15428 1/20 0.44
ITGB1 P05556 3/20 0.44
ITGA4 P13612 3/20 0.44
ITGB7 P26010 3/20 0.44
KMT2A Q03164 4/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4418816 0.91 ITGB1 (0.54) L3MBTL1HPGDITGB1ITGA4ITGB7
SCHEMBL3859687 0.90 CYP2C9 (0.47) CYP2C9CYP1A2CYP2C19L3MBTL1HPGD
SCHEMBL3859709 0.90 ITGB1 (0.44) ITGB1ITGA4ITGB7KMT2AMAPK1
SCHEMBL3855486 0.89 ITGB1 (0.45) ITGB1ITGA4ITGB7KMT2AMAPK1
SCHEMBL3858034 0.83 MAPK1 (0.48) ITGB1ITGA4KMT2AMAPK1SMN1; SMN2
SCHEMBL4422981 0.82 KMT2A (0.40) ITGB1ITGA4ITGB7KMT2AMAPK1
SCHEMBL3856996 0.81 P2RX7 (0.48) L3MBTL1ITGB1ITGA4ITGB7KMT2A
SCHEMBL3851225 0.81 P2RX7 (0.46) KMT2AMAPK1RAB9AMEN1
SCHEMBL3859375 0.80 P2RX7 (0.45) KMT2AMAPK1RAB9AMEN1
SCHEMBL3850947 0.79 ITGB3 (0.45) ITGB1ITGA4KMT2AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592387-A4 COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS ELAN PHARM INC (US) 2009-05-06 EP disclosed
EP-1592387-A2 COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS Elan Pharmaceuticals, Inc. (US) 2005-11-09 EP disclosed
WO-2004066932-A2 COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS ELAN PHARMACEUTICALS INC. (US) 2004-08-12 WO disclosed